Hans Bish­op gets a $287M pay­day as Juno ex­ecs see wind­fall for­tunes — with a $922M pay­off for Arch

In every big biotech buy­out the big win­ners are the share­hold­ers and every top ex­ec­u­tive at the com­pa­ny. And Juno Ther­a­peu­tics is no ex­cep­tion.

In their lat­est SEC fil­ing the biotech spelled out the wind­fall for­tunes that await­ed the ex­ec­u­tive crew, in­clud­ing the new­ly re­cruit­ed R&D chief Sunil Agar­w­al.

Top earn­ers gar­nered the most cash, start­ing with CEO Hans Bish­op.

Bish­op’s stock in the com­pa­ny is worth $205 mil­lion, with an ad­di­tion­al set of vest­ed and un­vest­ed op­tions reg­is­ter­ing $68 mil­lion and an­oth­er $8.6 mil­lion in re­strict­ed shares. That’s a $281.6 mil­lion pay­day, plus an­oth­er two years salary — $1.3 mil­lion cash — to get through the tran­si­tion. There’s al­so cov­ered CO­BRA and $3.4 mil­lion for his gold­en para­chute tax­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.